AbbVie
Denali and AbbVie’s ALS Candidates Fail Phase 2/3 Trials, Highlighting Challenges in ALS Research
ALS, Denali Therapeutics, AbbVie, Calico Life Sciences, HEALEY ALS Platform Trial, DNL343, fosigotifator, amyotrophic lateral sclerosis, clinical trials, drug development
AbbVie and Simcere Zaiming Collaborate on Novel Trispecific Antibody for Multiple Myeloma Treatment
AbbVie, Simcere Zaiming, multiple myeloma, trispecific antibody, SIM0500, T-cell engager, GPRC5D, BCMA, CD3
Capsida and AbbVie’s Gene Therapy Collaboration Yields Promising Results for Eye Diseases
Capsida Biotherapeutics, AbbVie, gene therapy, eye diseases, strategic collaboration, adeno-associated virus (AAV) engineering platform, ophthalmology, genetic medicines.
AbbVie Expands Immunology Pipeline with $200M Acquisition of Nimble Therapeutics
AbbVie, Nimble Therapeutics, Immunology, Psoriasis, Autoimmune Diseases, IL23R Inhibitor, Peptide Therapeutics
Alector Cuts 17% of Workforce Following Failure of AbbVie-Partnered Alzheimer’s Drug in Phase 2 Trial
Alector, layoffs, AbbVie, Alzheimer’s disease, phase 2 trial failure, biotech industry
AbbVie’s Schizophrenia Drug Fails in Phase II Trials, Casting Doubt on Neuroscience Strategy
AbbVie, schizophrenia, emraclidine, Phase II trials, Cerevel Therapeutics, neuroscience strategy, pharmaceutical industry
GSK Exits Biotechnology Innovation Organization (BIO) for 2025, Joining Takeda, UCB, and Others
GSK, BIO, Biotechnology Innovation Organization, Takeda, UCB, Pfizer, WuXi AppTec, AbbVie, pharmaceutical industry, trade group, lobbying
AbbVie and EvolveImmune Therapeutics Collaborate on Next-Generation Cancer Biotherapeutics Using T-Cell Engager Technology
AbbVie, EvolveImmune Therapeutics, T-Cell Engager Technology, Next-Generation Cancer Biotherapeutics, Oncology Collaboration, Multispecific Biologics, Cancer Cell Resistance, Immunotherapies
Skyrizi Surpasses Humira as AbbVie’s Top-Selling Drug
Skyrizi, Humira, AbbVie, revenue leader, immunology, plaque psoriasis, psoriatic arthritis, Crohn’s disease
AbbVie Expands CNS Capabilities with $1.4 Billion Acquisition of Aliada Therapeutics
AbbVie, Aliada Therapeutics, CNS diseases, Alzheimer’s disease, anti-amyloid asset, blood-brain barrier technology, MODEL platform, ALIA-1758, pharmaceutical acquisition